About us
Yi Chen, PhD
CSO
Specialized in rational drug design and preclinical development
Led the drug design and preclinical development with five drugs moved into various stages of clinical development:
EDO-S101 (Tinostamustine), dual-targeting DNA and HDAC
LP-168 (Rocbrutinib), a new generation BTK inhibitor
LP-108 (Lacutoclax), a selective and potent Bcl-2 inhibitor
LP-118, a new generation selective Bcl-2/Bcl-xL inhibitor
LP-128, a highly potent HBsAg inhibitor